Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 130 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: NSCLC, Early Stage Clear all
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 3, 2026, 5:26 AM EDT
Terminated Phase 4 Interventional Results available

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

NCT04381494
View directory record Official record
Conditions
Unresectable Stage III NSCLC
Interventions
Multiparametric Mobile Technology
Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Long Beach, California • Santa Ana, California • Englewood, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 3, 2026, 5:26 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

NCT07128199
View directory record Official record
Conditions
Lung Cancer, Adjuvant, Post-surgical, EGFR, Exon 20, Early Stage Lung Cancer, Uncommon EGFR Mutations, NSCLC, Early Stage
Interventions
TAS6417, Zipalertinib Matching-placebo
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
30
States / cities
Anchorage, Alaska • Duarte, California • Irvine, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 3, 2026, 5:26 AM EDT
Not listed No phase listed Observational

Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

NCT04712877
View directory record Official record
Conditions
NSCLC
Interventions
ctDNA, tumor NGS
Diagnostic Test
Lead sponsor
Lung Cancer Mutation Consortium
Network
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
21
States / cities
Davis, California • Los Angeles, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Sep 3, 2026, 5:26 AM EDT
Completed Early Phase 1 Interventional Results available

Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients

NCT01434342
View directory record Official record
Conditions
Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer, Prostate Cancer
Interventions
Nicotine Replacement Patch
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 3, 2026, 5:26 AM EDT
Completed Phase 1 Interventional

Photodynamic Therapy Plus Brachytherapy in Treating Patients With Lung Cancer

NCT00014066
View directory record Official record
Conditions
Lung Cancer
Interventions
hematoporphyrin derivative, brachytherapy
Drug · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 3, 2026, 5:26 AM EDT
Suspended Phase 1Phase 2 Interventional

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT06694454
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
Interventions
azacytidine, carboplatin, paclitaxel, durvalumab, cisplatin, gemcitabine, pemetrexed
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 3, 2026, 5:26 AM EDT
Completed Phase 1 Interventional

Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery

NCT00020007
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
isolated perfusion, paclitaxel, hyperthermia treatment
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 3, 2026, 5:26 AM EDT
Completed No phase listed Observational

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

NCT00897793
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions
venipuncture, radiation therapy
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Sep 3, 2026, 5:26 AM EDT
Recruiting Phase 2 Interventional

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

NCT07489066
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-squamous, Non-small Cell Lung Cancer, Squamous
Interventions
PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
7
States / cities
Huntsville, Alabama • Athens, Georgia • Hinsdale, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 3, 2026, 5:26 AM EDT
Active, not recruiting Phase 2 Interventional

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

NCT06161441
View directory record Official record
Conditions
Resectable Non-small Cell Lung Cancer
Interventions
Fianlimab, Cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
8
States / cities
Clermont, Florida • Chicago, Illinois • Westwood, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 3, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

NCT01262560
View directory record Official record
Conditions
Dysphagia, Lung Cancer, Pain, Esophagitis
Interventions
Manuka honey in liquid form, Manuka honey in lozenge form, Standard supportive care
Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
59
States / cities
Mobile, Alabama • San Francisco, California • Stanford, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 3, 2026, 5:26 AM EDT
Completed Phase 1 Interventional Results available

Intratumoral Cisplatin for Resectable NSCLC

NCT04809103
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
cis-diamminedichloroplatinum
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 3, 2026, 5:26 AM EDT
Terminated Phase 2 Interventional Results available

Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy

NCT00077064
View directory record Official record
Conditions
Lung Cancer, Pulmonary Complications, Radiation Fibrosis
Interventions
captopril
Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
87
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Sep 3, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

NCT01935336
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
Ponatinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Sep 3, 2026, 5:26 AM EDT
Completed Not applicable Interventional

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

NCT00002520
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
nicotine, Usual Care
Drug · Behavioral
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
19 Years to 120 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 3, 2026, 5:26 AM EDT
Recruiting Phase 3 Interventional

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

NCT07388524
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection, Computed Tomography, Patient Observation
Biological · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
59
States / cities
Beverly Hills, California • Los Angeles, California • Tarzana, California + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 3, 2026, 5:26 AM EDT
Withdrawn Phase 2 Interventional

Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer

NCT04061590
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
Interventions
Cisplatin, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Therapeutic Conventional Surgery
Drug · Biological · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 3, 2026, 5:26 AM EDT
Completed No phase listed Observational

Detection of Early Metastases in Patients With Stage I Non-small Cell Lung Cancer

NCT00003006
View directory record Official record
Conditions
Lung Cancer
Interventions
reverse transcriptase-polymerase chain reaction, immunohistochemistry staining method
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
10
States / cities
Iowa City, Iowa • Baltimore, Maryland • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Sep 3, 2026, 5:26 AM EDT
Terminated No phase listed Observational

Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up

NCT02121925
View directory record Official record
Conditions
Lung Cancer, NSCLC, Lung Adenocarcinoma
Interventions
Not listed
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Sep 3, 2026, 5:26 AM EDT
Completed No phase listed Observational

Utility of Routine Cervical Mediastinoscopy in Clinical Stage I Non-Small Cell Lung Cancer (NSCLC)

NCT01146366
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Jennifer Bell
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
4
States / cities
Atlanta, Georgia • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 3, 2026, 5:26 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171, Carboplatin, Cisplatin, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin, Carboplatin/Paclitaxel, Volrustomig, Rilvegostomig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 95 Years
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Oakland, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 3, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer

NCT00654030
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
1650-G Vaccine
Drug
Lead sponsor
Edward Hirschowitz
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Danville, Kentucky • Lexington, Kentucky • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2018 · Synced Sep 3, 2026, 5:26 AM EDT
Completed Not applicable Interventional Results available

Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer

NCT02394548
View directory record Official record
Conditions
Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma
Interventions
Contralateral Esophageal Sparing Technique (CEST)
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 3, 2026, 5:26 AM EDT